MDxHealth SA
NASDAQ:MDXH
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
52 Week Range |
1.57
4.48
|
Price Target |
|
We'll email you a reminder when the closing price reaches USD.
Choose the stock you wish to monitor with a price alert.
This alert will be permanently deleted.
Net Margin
MDxHealth SA
Net Margin measures how much net income is generated as a percentage of revenues received. It helps investors assess if a company's management is generating enough profit from its sales and whether operating costs and overhead costs are being contained.
Net Margin Across Competitors
Country | BE |
Market Cap | 96m USD |
Net Margin |
-50%
|
Country | FR |
Market Cap | 6T USD |
Net Margin |
-21 040%
|
Country | US |
Market Cap | 320.1B USD |
Net Margin |
9%
|
Country | US |
Market Cap | 150.5B USD |
Net Margin |
13%
|
Country | US |
Market Cap | 120.4B USD |
Net Margin |
-5%
|
Country | US |
Market Cap | 113.8B USD |
Net Margin |
0%
|
Country | US |
Market Cap | 94.1B EUR |
Net Margin |
-392%
|
Country | AU |
Market Cap | 135.4B AUD |
Net Margin |
18%
|
Country | US |
Market Cap | 82.9B USD |
Net Margin |
34%
|
Country | US |
Market Cap | 39.3B EUR |
Net Margin |
-33%
|
Country | NL |
Market Cap | 34.5B EUR |
Net Margin |
-14%
|
MDxHealth SA
Glance View
MDxHealth SA engages in the development and commercialization of molecular diagnostic products for personalized cancer treatment. The company is headquartered in Herstal, Liege. The company went IPO on 2006-06-26. The Company’s tests are based on proprietary genetic, epigenetic (methylation) and other molecular technologies and assist physicians with the diagnosis of urologic cancers, prognosis of recurrence risk, as well as prediction of response to a specific therapy. Its tests include ConfirmMDx for Prostate Cancer, SelectMDx for Prostate Cancer, PredictMDx for Glioblastoma and AssureMDx for Bladder Cancer. The firm's corporate operations are based in Herstal, Belgium, as well as Irvine, the United States, and its laboratory operations are based in Nijmegen, the Netherlands, as well as Irvine, the United States.
See Also
Net Margin measures how much net income is generated as a percentage of revenues received. It helps investors assess if a company's management is generating enough profit from its sales and whether operating costs and overhead costs are being contained.
Based on MDxHealth SA's most recent financial statements, the company has Net Margin of -49.5%.